Avestar Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,500
Closed -$1.24M 511
2025
Q1
$1.24M Sell
1,500
-800
-35% -$666K 0.11% 161
2024
Q4
$1.78M Buy
2,300
+2,000
+667% +$1.66M 0.15% 112
2024
Q3
$266K Sell
300
-200
-40% -$180K 0.03% 380
2024
Q2
$453K Hold
500
0.05% 261
2024
Q1
$389K Hold
500
0.04% 278
2023
Q4
$291K Hold
500
0.03% 301
2023
Q3
$269K Buy
+500
New +$258K 0.04% 275

Other funds holding LLY

Avestar Capital's LLY Position: Q2 2026 in Review

Avestar Capital increased its Eli Lilly (LLY) stake by 0.85% in Q2 2026, buying an estimated $72.5K and bringing the position to 8,456 shares worth $10.1M. The position accounts for 0.57% of the portfolio, ranked #33.

Avestar Capital first reported a position in LLY in Q4 2017 and has held it in 26 quarters since. 2,244 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Avestar Capital held 8,456 shares of Eli Lilly worth $10.1M as of Q2 2026.
  • Avestar Capital bought 71 Eli Lilly shares in Q2 2026, an estimated $72.5K.
  • Eli Lilly made up 0.57% of Avestar Capital's portfolio in Q2 2026, its #33 holding.
  • Avestar Capital first reported a position in Eli Lilly in Q4 2017 and has held it in 26 quarters since.
  • 2,244 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.